Published designs of specific CAR-NK cells use multiple peptides as targeting molecules, allowing for the simultaneous targeting of tumor-associated antigens (TAAs) featuring PD-L1, EGFR, and VEGFR2 [167]. Here, CD274 is linked to neoplasm.